Targeting Cul3-scaffold E3 ligase complex via KLHL substrate adaptors for cancer therapy

Pharmacol Res. 2021 Jul:169:105616. doi: 10.1016/j.phrs.2021.105616. Epub 2021 Apr 17.

Abstract

Targeted therapy has become increasingly important and indispensable in cancer therapy. Cullin3-RING ligases (CRL3) serve as essential executors for regulating protein homeostasis in cancer development, highlighting that CRL3 might be promising targets in various cancer treatment. However, how to design new targeted therapies by disrupting the function of CRL3 is poorly understood. Here, we focus on the substrate adaptors of CRL3, and carry out a systematical research on the function of Kelch-like (KLHL) family proteins. We have identified twenty-four KLHL proteins with function of tumor promotion and thirteen KLHL proteins with high clinical significance on cancer therapy. Furthermore, we have clarified the novel biological function of KLHL13 as a vital factor that contributes to malignant progression in lung cancer. Taken together, our findings reveal multiple potential therapeutical targets and provide evidence for targeting CRL3 via KLHL substrate adaptors for cancer therapy.

Keywords: Cancer therapy; Cullin3-RING Ligase; KLHL; Substrate adaptor; Target discovery.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Line, Tumor
  • Colonic Neoplasms / drug therapy
  • Colonic Neoplasms / metabolism
  • Cullin Proteins / metabolism*
  • Female
  • Humans
  • Kelch Repeat*
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / metabolism
  • Molecular Targeted Therapy / methods*
  • Neoplasm Proteins / metabolism*
  • Neoplasms / drug therapy
  • Neoplasms / metabolism*
  • Neoplasms / pathology
  • Ovarian Neoplasms / drug therapy
  • Ovarian Neoplasms / metabolism
  • Ubiquitin-Protein Ligases / metabolism*

Substances

  • CUL3 protein, human
  • Cullin Proteins
  • Neoplasm Proteins
  • Ubiquitin-Protein Ligases